LASIK could now be possible in patients previously excluded

Article

Epithelial thickness profiles may make it possible for LASIK to be performed in eyes that may otherwise have been excluded because of topographic suspect keratoconus.

Epithelial thickness profiles may make it possible for LASIK to be performed in eyes that may otherwise have been excluded because of topographic suspect keratoconus, according to Dan Reinstein and colleagues from the London Vision Clinic, London, UK.

In his study, eyes suspected of keratoconus were scanned with Artemis very high-frequency (VHF) digital ultrasound. A diagnosis was confirmed if the epithelial thickness profile demonstrated relative epithelial thinning coincident with the topographically suspected cone.

LASIK was then performed in all eyes where keratoconus was excluded by finding relatively thicker epithelium over the topographically suspected cone. Patients were followed for one year and a matched control group was randomly generated to compare refractive outcomes.

Out of a total of 1,352 consecutive myopic eyes, 104 (7.7%) were classified as keratoconus suspects. After Artemis scanning, 14 eyes (17%) were confirmed as having keratoconus and 90 eyes (40 subjects) were found to be non-keratoconic and underwent LASIK. A control for each study eye was matched within 0.50 D for sphere, cylinder and spherical equivalent (SE). The average change in SE between three months and one-year follow-up was -0.03 D for the keratconus suspect group and -0.09 D for the control group.

The researchers concluded that epithelial thickness profiles may allow LASIK to be performed in eyes that, in the past, would have been excluded because of topographic suspect keratoconus.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.